Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.

Introducción: El cáncer de mama es una enfermedad heterogénea y fenotípica- mente diversa compuesta por varios subtipos biológicos que tienen un comporta- miento distinto. La amplificación o sobreexpresión del oncogén del receptor 2 del factor de crecimiento epidérmico humano (HER2) está presente en...

Full description

Autores:: Espinosa, David

Tipo de recurso:: Trabajo de grado de pregrado

Fecha de publicación:: 2021

Institución:: Universidad Militar Nueva Granada

Repositorio:: Repositorio UMNG

Idioma:: spa

id	UNIMILTAR2_8091d6b994ef6235e8bc8d952c3ff413
oai_identifier_str	oai:repository.unimilitar.edu.co:10654/39881
network_acronym_str	UNIMILTAR2
network_name_str	Repositorio UMNG
repository_id_str
dc.title.spa.fl_str_mv	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.
dc.title.translated.spa.fl_str_mv	Overall survival of patients with stage IV HER-2 positive advanced breast cancer treated at the Hospital Militar Central de Colombia between 2014 and 2018.
title	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.
spellingShingle	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018. Her2 Metástasis Cáncer Breast NEOPLASIAS DE LA MAMA ANTINEOPLASICOS ONCOLOGIA MEDICA Her2 Metastasis Cáncer Mama
title_short	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.
title_full	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.
title_fullStr	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.
title_full_unstemmed	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.
title_sort	Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.
dc.creator.fl_str_mv	Espinosa, David
dc.contributor.advisor.none.fl_str_mv	Segovia Gomez, Javier Cantor, Erick
dc.contributor.author.none.fl_str_mv	Espinosa, David
dc.subject.keywords.spa.fl_str_mv	Her2 Metástasis Cáncer Breast
topic	Her2 Metástasis Cáncer Breast NEOPLASIAS DE LA MAMA ANTINEOPLASICOS ONCOLOGIA MEDICA Her2 Metastasis Cáncer Mama
dc.subject.decs.spa.fl_str_mv	NEOPLASIAS DE LA MAMA ANTINEOPLASICOS ONCOLOGIA MEDICA
dc.subject.proposal.spa.fl_str_mv	Her2 Metastasis Cáncer Mama
description	Introducción: El cáncer de mama es una enfermedad heterogénea y fenotípica- mente diversa compuesta por varios subtipos biológicos que tienen un comporta- miento distinto. La amplificación o sobreexpresión del oncogén del receptor 2 del factor de crecimiento epidérmico humano (HER2) está presente en aproximada- mente el 15 al 20 por ciento de los cánceres de mama invasivos primarios. La so- breexpresión de HER2 se asocia con altas tasas de recurrencia de la enfermedad y mortalidad en ausencia de terapia sistémica. Objetivo: Caracterizar clínicamente la población con diagnóstico de cáncer de mama HER2 positivo estadio avanzado en el subsistema de las Fuerzas Militares, con los datos disponibles en el Hospital Militar Central entre 2014 y 2018 y descri- bir su supervivencia. Metodología: Describir la supervivencia global por medio de un análisis de Kaplan Meyer de los pacientes mayores de 18 años diagnosticados con cáncer de mama HER2+ en estadio avanzado que recibieron tratamiento entre el 2014 y el 2018. Resultados esperados: Socializar en la comunidad científica nacional y local la su- pervivencia a de las personas con ca de seno avanzado tratados en el Hospital Militar Central de Colombia
publishDate	2021
dc.date.accessioned.none.fl_str_mv	2021-12-30T15:04:41Z
dc.date.available.none.fl_str_mv	2021-12-30T15:04:41Z
dc.date.issued.none.fl_str_mv	2021-11-22
dc.type.local.spa.fl_str_mv	Tesis/Trabajo de grado - Monografía - Especialización
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.type.coar.*.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
format	http://purl.org/coar/resource_type/c_7a1f
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10654/39881
dc.identifier.instname.spa.fl_str_mv	instname:Universidad Militar Nueva Granada
dc.identifier.reponame.spa.fl_str_mv	reponame:Repositorio Institucional Universidad Militar Nueva Granada
dc.identifier.repourl.spa.fl_str_mv	repourl:https://repository.unimilitar.edu.co
url	http://hdl.handle.net/10654/39881
identifier_str_mv	instname:Universidad Militar Nueva Granada reponame:Repositorio Institucional Universidad Militar Nueva Granada repourl:https://repository.unimilitar.edu.co
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Can- cer J Clin. 2021 Jan 12;71(1):7–33. Organización Mundial de la Salud Agencia Internacional para la Investiga- ción del Cáncer. El Observatorio Global del Cáncer. Estadísticas 2018. 2018. Aid For Trade Country Fact Sheets: Colombia. Organisation for Economic Co-Operation and Development (OECD); Gress DM, Edge SB, Greene FL, Washington MK, Asare EA, Brierley JD, et al. Principles of Cancer Staging. AJCC Cancer Staging Manual. Springer In- ternational Publishing; 2016. p. 3–30. Esserman LJ, Shieh Y, Rutgers EJT, Knauer M, Retèl VP, Mook S, et al. Im- pact of mammographic screening on the detection of good and poor progno- sis breast cancers. Breast Cancer Res Treat. 2011 Dec 4;130(3):725–34. Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malig- nant lesions. Radiology. 1995 Jul;196(1):123–34. Macura KJ, Ouwerkerk R, Jacobs MA, Bluemke DA. Patterns of Enhance- ment on Breast MR Images: Interpretation and Imaging Pitfalls. RadioGraph- ics. 2006 Nov;26(6):1719–34. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: How special are they? Mol Oncol. 2010;4(3):192–208. Nascimento RG do, Otoni KM. Histological and molecular classification of breast cancer: what do we know? Mastology. 2020;30:1–8. Dizon DS, Tejada-Berges T, Steinhoff MM et al. Breast Cancer. In: RR Barakat, M Markman MR, editor. Principles and Practice of Gynecologic On- cology. 5th ed. Baltimore: Lippincott, Williams, & Wilkins; 2009. p. 910. Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol. 2013 Feb 20;15(2):126–34 Parise CA, Bauer KR, Brown MM, Caggiano V. Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. Breast J. 2009 Nov;15(6):593–602. O’Brien KM, Cole SR, Tse C-K, Perou CM, Carey LA, Foulkes WD, et al. In- trinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010 Dec 15;16(24):6100–10. Guler EN. Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer. Eur J Breast Heal. 2017;13(4):168–74 Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001 Sep;98(19):10869 LP – 10874. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast can- cer: the CTNeoBC pooled analysis. Lancet. 2014 Jul;384(9938):164–72. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016 Jun;2(6):751–60. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Apr;35(10):1049–60. Selli C, Sims AH. Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research. Breast Cancer Basic Clin Res. 2019;13. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assess- ment and systemic therapy issues in operable disease. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Feb;26(5):814–9. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an up- date. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Apr;24(12):1940–9. Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23(SUPPL. 10). Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004 Jun;100(12):2512–32 Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effec- tively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Sep;30(26):3242–9. Wuerstlein R, Harbeck N. Neoadjuvant Therapy for HER2-positive Breast Cancer. Rev Recent Clin Trials. 2017;12(2):81–92. Warner ET, Ballman K V, Strand C, Boughey JC, Buzdar AU, Carey LA, et al. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kem- per I, Dezentjé VO, et al. Neoadjuvant chemotherapy with or without anth- racyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lan- cet Oncol. 2018;19(12):1630–40 Bayraktar S, Bayraktar UD, Reis IM, Pegram M, Welsh C, Silva O, et al. Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer. J Clin On- col. 2009;27(15_suppl):e11557–e11557. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CEJ, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct;353(16):1673–84. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Per- tuzumab plus trastuzumab in combination with standard neoadjuvant anthra- cycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–84. Gianni L, Pienkowski T, Im Y-H, Tseng L-M, Liu M-C, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (Neo- Sphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791–800. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with local- ly advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25–32 Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled su- periority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014 May;15(6):640–7 Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2- positive breast cancer (Z1041): a random. Lancet Oncol. 2013;14(13):1317– 25. Robidoux A, Tang G, Rastogi P, Geyer CEJ, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183–92 Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J-U, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline- taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135–44. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a ran- domised controlled superiority trial with a parallel HE. Lancet (London, Eng- land). 2010 Jan;375(9712):377–84 Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, et al. Pertuzumab: New hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82 Swain SM, Kim S-B, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertu- zumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461–71. van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kem- per I, Vulink AJ, et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021 May; Slamon N, Penfil S, Deutsch E, Nadkarni V. Biometric stress tracking and analysis during acute ICU care using a novel biosensing garment. Crit Care Med. 2016;44(12):358. World Health Organization. Renal cancer. The Global Cancer Observatory. 2019. p. 1–2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–92 Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic dis- ease. J Clin Oncol. 1999 Sep;17(9):2639–48 Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. J Clin Oncol. 2005 Jul 1;23(19):4265– 74 Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Supervivencia en pacientes con cáncer de mama recurrente metastásico después de quimioterapia adyuvan- te: poca evidencia de mejoría en los últimos 30 años. Cancer 2013; 119: 1140 Grupo colaborativo de investigadores del cáncer de mama temprano (EB- CTCG). Efectos de la quimioterapia y la terapia hormonal para el cáncer de mama temprano sobre la recurrencia y la supervivencia a 15 años: una des- cripción general de los ensayos aleatorios. Lancet 2005; 365: 1687. Chia SK, Speers CH, D'yachkova Y, et al. El impacto de nuevos agentes qui- mioterapéuticos y hormonales en la supervivencia en una cohorte poblacio- nal de mujeres con cáncer de mama metastásico. Cancer 2007; 110: 973. Gennari A, Conte P, Rosso R, et al. Supervivencia de pacientes con carcinoma de mama metastásico durante un período de 20 años: un análisis retrospec- tivo basado en datos de pacientes individuales de seis estudios consecuti- vos. Cancer 2005; 104: 1742 Dafni U, Grimani I, Xyrafas A, et al. Tendencias de quince años en la supervi- vencia del cáncer de mama metastásico en Grecia. Tratamiento contra el cáncer de mama 2010; 119: 621 Johnston SRD, Hegg R, Im SA, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapati- nib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Post- menopausal Women With HER2-Positive, Hormone Receptor-Positive Me- tastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol 2021; 39:79
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.accessrights.*.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.spa.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.local.spa.fl_str_mv	Acceso abierto
rights_invalid_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International Acceso abierto
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	applicaction/pdf
dc.coverage.spatial.spa.fl_str_mv	Hospital Militar Central de Bogotá.
dc.coverage.temporal.spa.fl_str_mv	01 de septiembre hasta 31 de octubre de 2021
dc.coverage.sede.spa.fl_str_mv	Medicina
dc.publisher.program.spa.fl_str_mv	Hematología y Oncología Clínica
dc.publisher.faculty.spa.fl_str_mv	Facultad de Medicina
dc.publisher.grantor.spa.fl_str_mv	Universidad Militar Nueva Granada
institution	Universidad Militar Nueva Granada
bitstream.url.fl_str_mv	http://repository.unimilitar.edu.co/bitstream/10654/39881/1/upervivencia%20global%20de%20los%20pacientes%20con%20Ca%cc%81ncer%20de%20Mama%20HER-2%20positivo%20Avanzado%20Estadio%20IV%20atendidos%20en%20el%20Hospital%20Militar%20Central%20de%20Colombia%20entre%20el%20an%cc%83o%202014%20y%202018.pdf http://repository.unimilitar.edu.co/bitstream/10654/39881/2/SUPERVIVENCIA%20GLOBAL%20DE%20PACIENTES%20CON%20CANCER%20DE%20MAMA%20HER2%20POSITIVO%20ESTADIO%20AVANZADO.pdf http://repository.unimilitar.edu.co/bitstream/10654/39881/3/license.txt http://repository.unimilitar.edu.co/bitstream/10654/39881/4/upervivencia%20global%20de%20los%20pacientes%20con%20Ca%cc%81ncer%20de%20Mama%20HER-2%20positivo%20Avanzado%20Estadio%20IV%20atendidos%20en%20el%20Hospital%20Militar%20Central%20de%20Colombia%20entre%20el%20an%cc%83o%202014%20y%202018.pdf.jpg http://repository.unimilitar.edu.co/bitstream/10654/39881/5/SUPERVIVENCIA%20GLOBAL%20DE%20PACIENTES%20CON%20CANCER%20DE%20MAMA%20HER2%20POSITIVO%20ESTADIO%20AVANZADO.pdf.jpg
bitstream.checksum.fl_str_mv	a2f229c66c3a10c46a620e0cb9e83b73 24b35d27c430ce11fd0818a9187f8e47 a609d7e369577f685ce98c66b903b91b 0f575f31fc1add8224b24020a0a43fef f6238e78ea762811a20ea4896ba738ae
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional UMNG
repository.mail.fl_str_mv	bibliodigital@unimilitar.edu.co
_version_	1837098498982412288
spelling	Segovia Gomez, JavierCantor, ErickEspinosa, DavidEspecialista en Hematología y Oncología ClínicaHospital Militar Central de Bogotá.01 de septiembre hasta 31 de octubre de 2021Medicina2021-12-30T15:04:41Z2021-12-30T15:04:41Z2021-11-22http://hdl.handle.net/10654/39881instname:Universidad Militar Nueva Granadareponame:Repositorio Institucional Universidad Militar Nueva Granadarepourl:https://repository.unimilitar.edu.coIntroducción: El cáncer de mama es una enfermedad heterogénea y fenotípica- mente diversa compuesta por varios subtipos biológicos que tienen un comporta- miento distinto. La amplificación o sobreexpresión del oncogén del receptor 2 del factor de crecimiento epidérmico humano (HER2) está presente en aproximada- mente el 15 al 20 por ciento de los cánceres de mama invasivos primarios. La so- breexpresión de HER2 se asocia con altas tasas de recurrencia de la enfermedad y mortalidad en ausencia de terapia sistémica. Objetivo: Caracterizar clínicamente la población con diagnóstico de cáncer de mama HER2 positivo estadio avanzado en el subsistema de las Fuerzas Militares, con los datos disponibles en el Hospital Militar Central entre 2014 y 2018 y descri- bir su supervivencia. Metodología: Describir la supervivencia global por medio de un análisis de Kaplan Meyer de los pacientes mayores de 18 años diagnosticados con cáncer de mama HER2+ en estadio avanzado que recibieron tratamiento entre el 2014 y el 2018. Resultados esperados: Socializar en la comunidad científica nacional y local la su- pervivencia a de las personas con ca de seno avanzado tratados en el Hospital Militar Central de ColombiaCONTENIDO. 3. RESUMEN ......................................................................................... 5 4. MARCO TEÓRICO ............................................................................ 6 Epidemiología .................................................................................. 6 Diagnóstico ...................................................................................... 7 Tratamiento ............................ .........................................................12 5. IDENTIFICACION Y FORMULACION DEL PROBLEMA ........................... 25 6. JUSTIFICACIÓN ............................................................................... 28 6.1 PREGUNTA DE INVESTIGACIÓN .......................................................29 7. OBJETIVOS .....................................................................................29 7.1 GENERAL .................................................................................. 29 7.2 ESPECIFICOS ............................................................................ 30 8. METODOLOGÍA ............................................................................... 31 8.1 Tipo y diseño general del estudio ...................................................31 8.2 Población .................. ..............................................................31 8.3 Selección de la muestra y recolección de datos .............................31 8.4 CRITERIOS DE INCLUSIÓN EXCLUSIÓN............................................32 8.4.1 Criterios de inclusion ..............................................................32 8.4.2 Criterios de exclusión ............................................................. 32 8.5 Intervención propuesta ...............................................................33 8.6 Plan de recolección de la información ......................................... 33 8.7 Fuentes de recolección de información ........................................33 8.8 Instrumento recolección de información .......................................34 9. DEFINICION DE VARIABLES .............................................................. 35 10. PLAN DE ANALISIS .........................................................................37 10.1 Proceso de obtención información ............................................... 37 10.2 Estrategias para suprimir amenazas a la validez de resultados y control de sesgos y errores .............................................................................37 10.3 Procesamiento y análisis estadístico ...............................................39 11. RESULTADOS/PRODUCTOS ESPERADOS Y POTENCIALES BENEFICIA- RIOS. ..................................................................................................41 12. CRONOGRAMA ..............................................................................44 13. PRESUPUESTO...............................................................................45 14. ASPECTOS ETICOS .........................................................................46 15. RESULTADOS ................................................................................48 16. DISCUSION ....................................................................................51 17. CONCLUSION................................................................................56 18. INDICE DE TABLAS Y FIGURAS ........................................................58 19. ANEXOS .........................................................................................59 20. REFERENCIAS BIBLIOGRAFICAS .......... ..........................................65Summary. Introduction: Breast cancer is a heterogeneous and phenotypically diverse disease composed of several biological subtypes that have different behavior. Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene is present in approximately 15 to 20 percent of primary invasive breast cancers. HER2 overexpression is associated with high rates of disease recurrence and mortality in the absence of systemic therapy. Objective: To clinically characterize the population with a diagnosis of advanced stage HER2 positive breast cancer in the subsystem of the Military Forces, with the data available at the Central Military Hospital between 2014 and 2018 and describe their survival. Methodology: Describe overall survival through a Kaplan Meier analysis of patients older than 18 years diagnosed with advanced-stage HER2 + breast cancer who received treatment between 2014 and 2018. 2 Results: 21 patients were included with a median follow-up of 24 months (IQR 6.5-30.5). The median overall survival (OS) estimated was 18 months. Patients with more than one organ involved median OS 12 months (IQR 7.5-40.5). Hormone receptor positive patients had better overall survival (42 months) compared to hormone receptor negative patients (10 months) Conclusion: Overall survival is lower, compared to the data reported in different international studies.Especializaciónapplicaction/pdfspahttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 InternationalAcceso abiertoSupervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.Overall survival of patients with stage IV HER-2 positive advanced breast cancer treated at the Hospital Militar Central de Colombia between 2014 and 2018.Tesis/Trabajo de grado - Monografía - Especializacióninfo:eu-repo/semantics/bachelorThesishttp://purl.org/coar/resource_type/c_7a1fHer2MetástasisCáncerBreastNEOPLASIAS DE LA MAMAANTINEOPLASICOSONCOLOGIA MEDICAHer2MetastasisCáncerMamaHematología y Oncología ClínicaFacultad de MedicinaUniversidad Militar Nueva GranadaSiegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Can- cer J Clin. 2021 Jan 12;71(1):7–33.Organización Mundial de la Salud Agencia Internacional para la Investiga- ción del Cáncer. El Observatorio Global del Cáncer. Estadísticas 2018. 2018.Aid For Trade Country Fact Sheets: Colombia. Organisation for Economic Co-Operation and Development (OECD);Gress DM, Edge SB, Greene FL, Washington MK, Asare EA, Brierley JD, et al. Principles of Cancer Staging. AJCC Cancer Staging Manual. Springer In- ternational Publishing; 2016. p. 3–30.Esserman LJ, Shieh Y, Rutgers EJT, Knauer M, Retèl VP, Mook S, et al. Im- pact of mammographic screening on the detection of good and poor progno- sis breast cancers. Breast Cancer Res Treat. 2011 Dec 4;130(3):725–34.Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malig- nant lesions. Radiology. 1995 Jul;196(1):123–34.Macura KJ, Ouwerkerk R, Jacobs MA, Bluemke DA. Patterns of Enhance- ment on Breast MR Images: Interpretation and Imaging Pitfalls. RadioGraph- ics. 2006 Nov;26(6):1719–34.Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: How special are they? Mol Oncol. 2010;4(3):192–208.Nascimento RG do, Otoni KM. Histological and molecular classification of breast cancer: what do we know? Mastology. 2020;30:1–8.Dizon DS, Tejada-Berges T, Steinhoff MM et al. Breast Cancer. In: RR Barakat, M Markman MR, editor. Principles and Practice of Gynecologic On- cology. 5th ed. Baltimore: Lippincott, Williams, & Wilkins; 2009. p. 910.Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol. 2013 Feb 20;15(2):126–34Parise CA, Bauer KR, Brown MM, Caggiano V. Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. Breast J. 2009 Nov;15(6):593–602.O’Brien KM, Cole SR, Tse C-K, Perou CM, Carey LA, Foulkes WD, et al. In- trinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010 Dec 15;16(24):6100–10.Guler EN. Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer. Eur J Breast Heal. 2017;13(4):168–74Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001 Sep;98(19):10869 LP – 10874.Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast can- cer: the CTNeoBC pooled analysis. Lancet. 2014 Jul;384(9938):164–72.Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016 Jun;2(6):751–60.Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Apr;35(10):1049–60.Selli C, Sims AH. Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research. Breast Cancer Basic Clin Res. 2019;13.Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assess- ment and systemic therapy issues in operable disease. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Feb;26(5):814–9.Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an up- date. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Apr;24(12):1940–9.Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23(SUPPL. 10).Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004 Jun;100(12):2512–32Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effec- tively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Sep;30(26):3242–9.Wuerstlein R, Harbeck N. Neoadjuvant Therapy for HER2-positive Breast Cancer. Rev Recent Clin Trials. 2017;12(2):81–92.Warner ET, Ballman K V, Strand C, Boughey JC, Buzdar AU, Carey LA, et al. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancervan Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kem- per I, Dezentjé VO, et al. Neoadjuvant chemotherapy with or without anth- racyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lan- cet Oncol. 2018;19(12):1630–40Bayraktar S, Bayraktar UD, Reis IM, Pegram M, Welsh C, Silva O, et al. Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer. J Clin On- col. 2009;27(15_suppl):e11557–e11557.Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CEJ, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct;353(16):1673–84.Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Per- tuzumab plus trastuzumab in combination with standard neoadjuvant anthra- cycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–84.Gianni L, Pienkowski T, Im Y-H, Tseng L-M, Liu M-C, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (Neo- Sphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791–800.Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with local- ly advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25–32Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled su- periority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014 May;15(6):640–7Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2- positive breast cancer (Z1041): a random. Lancet Oncol. 2013;14(13):1317– 25.Robidoux A, Tang G, Rastogi P, Geyer CEJ, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183–92Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J-U, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline- taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135–44.Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a ran- domised controlled superiority trial with a parallel HE. Lancet (London, Eng- land). 2010 Jan;375(9712):377–84Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, et al. Pertuzumab: New hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82Swain SM, Kim S-B, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertu- zumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461–71.van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kem- per I, Vulink AJ, et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021 May;Slamon N, Penfil S, Deutsch E, Nadkarni V. Biometric stress tracking and analysis during acute ICU care using a novel biosensing garment. Crit Care Med. 2016;44(12):358.World Health Organization. Renal cancer. The Global Cancer Observatory. 2019. p. 1–2.Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–92Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic dis- ease. J Clin Oncol. 1999 Sep;17(9):2639–48Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. J Clin Oncol. 2005 Jul 1;23(19):4265– 74Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Supervivencia en pacientes con cáncer de mama recurrente metastásico después de quimioterapia adyuvan- te: poca evidencia de mejoría en los últimos 30 años. Cancer 2013; 119: 1140Grupo colaborativo de investigadores del cáncer de mama temprano (EB- CTCG). Efectos de la quimioterapia y la terapia hormonal para el cáncer de mama temprano sobre la recurrencia y la supervivencia a 15 años: una des- cripción general de los ensayos aleatorios. Lancet 2005; 365: 1687.Chia SK, Speers CH, D'yachkova Y, et al. El impacto de nuevos agentes qui- mioterapéuticos y hormonales en la supervivencia en una cohorte poblacio- nal de mujeres con cáncer de mama metastásico. Cancer 2007; 110: 973.Gennari A, Conte P, Rosso R, et al. Supervivencia de pacientes con carcinoma de mama metastásico durante un período de 20 años: un análisis retrospec- tivo basado en datos de pacientes individuales de seis estudios consecuti- vos. Cancer 2005; 104: 1742Dafni U, Grimani I, Xyrafas A, et al. Tendencias de quince años en la supervi- vencia del cáncer de mama metastásico en Grecia. Tratamiento contra el cáncer de mama 2010; 119: 621Johnston SRD, Hegg R, Im SA, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapati- nib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Post- menopausal Women With HER2-Positive, Hormone Receptor-Positive Me- tastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol 2021; 39:79ORIGINALupervivencia global de los pacientes con Cáncer de Mama HER-2 positivo Avanzado Estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.pdfupervivencia global de los pacientes con Cáncer de Mama HER-2 positivo Avanzado Estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.pdfEspinosaPuelloDavid2021.pdfapplication/pdf1498082http://repository.unimilitar.edu.co/bitstream/10654/39881/1/upervivencia%20global%20de%20los%20pacientes%20con%20Ca%cc%81ncer%20de%20Mama%20HER-2%20positivo%20Avanzado%20Estadio%20IV%20atendidos%20en%20el%20Hospital%20Militar%20Central%20de%20Colombia%20entre%20el%20an%cc%83o%202014%20y%202018.pdfa2f229c66c3a10c46a620e0cb9e83b73MD51SUPERVIVENCIA GLOBAL DE PACIENTES CON CANCER DE MAMA HER2 POSITIVO ESTADIO AVANZADO.pdfSUPERVIVENCIA GLOBAL DE PACIENTES CON CANCER DE MAMA HER2 POSITIVO ESTADIO AVANZADO.pdfEspinosaPuelloDavid2021_Articulo.pdfapplication/pdf247783http://repository.unimilitar.edu.co/bitstream/10654/39881/2/SUPERVIVENCIA%20GLOBAL%20DE%20PACIENTES%20CON%20CANCER%20DE%20MAMA%20HER2%20POSITIVO%20ESTADIO%20AVANZADO.pdf24b35d27c430ce11fd0818a9187f8e47MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-83420http://repository.unimilitar.edu.co/bitstream/10654/39881/3/license.txta609d7e369577f685ce98c66b903b91bMD53THUMBNAILupervivencia global de los pacientes con Cáncer de Mama HER-2 positivo Avanzado Estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.pdf.jpgupervivencia global de los pacientes con Cáncer de Mama HER-2 positivo Avanzado Estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.pdf.jpgIM Thumbnailimage/jpeg7574http://repository.unimilitar.edu.co/bitstream/10654/39881/4/upervivencia%20global%20de%20los%20pacientes%20con%20Ca%cc%81ncer%20de%20Mama%20HER-2%20positivo%20Avanzado%20Estadio%20IV%20atendidos%20en%20el%20Hospital%20Militar%20Central%20de%20Colombia%20entre%20el%20an%cc%83o%202014%20y%202018.pdf.jpg0f575f31fc1add8224b24020a0a43fefMD54SUPERVIVENCIA GLOBAL DE PACIENTES CON CANCER DE MAMA HER2 POSITIVO ESTADIO AVANZADO.pdf.jpgSUPERVIVENCIA GLOBAL DE PACIENTES CON CANCER DE MAMA HER2 POSITIVO ESTADIO AVANZADO.pdf.jpgIM Thumbnailimage/jpeg9095http://repository.unimilitar.edu.co/bitstream/10654/39881/5/SUPERVIVENCIA%20GLOBAL%20DE%20PACIENTES%20CON%20CANCER%20DE%20MAMA%20HER2%20POSITIVO%20ESTADIO%20AVANZADO.pdf.jpgf6238e78ea762811a20ea4896ba738aeMD5510654/39881oai:repository.unimilitar.edu.co:10654/398812022-01-10 01:03:11.563Repositorio Institucional UMNGbibliodigital@unimilitar.edu.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

Supervivencia global de los pacientes con cáncer de mama HER-2 positivo avanzado estadio IV atendidos en el Hospital Militar Central de Colombia entre el año 2014 y 2018.

Publicaciones similares